Granted Patent
B2
US 12,227,584 · App. 17/398,851 · Granted Feb 18, 2025
Multivalent and multispecific OX40-binding fusion proteins
Inventors:
Brendan P. Eckelman (Encinitas, CA); John C. Timmer (San Diego, CA); Chelsie Macedo (La Jolla, CA); Kyle S. Jones (San Marcos, CA); Abrahim Hussain (La Jolla, CA); Amir S. Razai (La Jolla, CA); Bryan Becklund (San Diego, CA); Rajay Pandit (La Jolla, CA); Mike Kaplan (La Jolla, CA); Lucas Rascon (La Jolla, CA); Quinn Deveraux (La Jolla, CA)
Assignee:
Inhibrx Biosciences, Inc.
C07K16/2878C07K16/2827A61K2039/505C07K2317/24C07K2317/31C07K2317/33C07K2317/35C07K2317/52C07K2317/569C07K2317/75C07K2317/76C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
Claims (18)
1. A method of treating cancer in a human subject having cancer comprising administering to the subject an isolated polypeptide that binds human OX40 and comprises at least one VHH that binds to OX40, wherein the at least one VHH that binds to OX40 comprises a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 36, a complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 37, and a complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 42.
2. The method of claim 1 , wherein the isolated polypeptide is monospecific.
3. The method of claim 1 , wherein the isolated polypeptide comprises at least two VHHs, and wherein at least two VHHs of the isolated polypeptide are operably linked via a linker polypeptide that consists of 5-20 amino acids, wherein the linker polypeptide is composed predominantly of glycine and serine.
4. The method of claim 1 , wherein the isolated polypeptide comprises an immunoglobulin Fc region polypeptide.
5. The method of claim 4 , wherein the immunoglobulin Fc region polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6.
6. The method of claim 1 , wherein the at least one VHH that binds to OX40 is a humanized VHH.
7. The method of claim 1 , wherein the at least one VHH that binds to OX40 comprises an amino acid sequence selected from SEQ ID NOs: 25 and 377-385.
8. The method of claim 1 , wherein the isolated polypeptide is dimeric and each molecule of the dimer comprises the structure: VHH-Linker-VHH-Linker-Hinge-Fc or VHH-Linker-VHH-Linker-VHH-Linker-Hinge-Fc, wherein each VHH is a humanized VHH.
9. The method of claim 1 , wherein the isolated polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 389-394.
10. A method of modulating immune cells to enhance tumor destruction in a human subject having cancer comprising administering to the subject an isolated polypeptide that binds human OX40 and comprises at least one VHH that binds to OX40, wherein the at least one VHH that binds to OX40 comprises a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 36, a complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 37, and a complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 42.
11. The method of claim 10 , wherein the isolated polypeptide is monospecific.
12. The method of claim 10 , wherein the isolated polypeptide comprises at least two VHHs, and wherein at least two VHHs of the isolated polypeptide are operably linked via a linker polypeptide that consists of 5-20 amino acids, wherein the linker polypeptide is composed predominantly of glycine and serine.
13. The method of claim 10 , wherein the isolated polypeptide comprises an immunoglobulin Fc region polypeptide.
14. The method of claim 13 , wherein the immunoglobulin Fc region polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6.
15. The method of claim 10 , wherein the at least one VHH that binds to OX40 is a humanized VHH.
16. The method of claim 10 , wherein the at least one VHH that binds to OX40 comprises an amino acid sequence selected from SEQ ID NOs: 25 and 377-385.
17. The method of claim 10 , wherein the isolated polypeptide is dimeric and each molecule of the dimer comprises the structure: VHH-Linker-VHH-Linker-Hinge-Fc or VHH-Linker-VHH-Linker-VHH-Linker-Hinge-Fc, wherein each VHH is a humanized VHH.
18. The method of claim 10 , wherein the isolated polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 389-394.
Assignments (4)
SECURITY INTEREST
Recorded Jan 14, 2025
From: INHIBRX BIOSCIENCES, INC.
To: OXFORD FINANCE LLC; OXFORD FINANCE LLC
Reel/Frame 069894/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0635 →
RELEASE OF SECURITY INTEREST
Recorded Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded Feb 28, 2022
From: INHIBRX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 059262/0780 →
Continuity (4)
Provisional Application
62277027
· Jan 11, 2016
References Cited (144)
US 5151510A
· Stec et al.
· 1992
[cited by applicant]
US 7959925B2
· Weinberg et al.
· 2011
[cited by applicant]
US 8614295B2
· Lawson et al.
· 2013
[cited by applicant]
US 20030157108A1
· Presta
· 2003
[cited by applicant]
US 20040029129A1
· Wang et al.
· 2004
[cited by applicant]
US 20040123343A1
· La Rosa et al.
· 2004
[cited by applicant]
US 20040214272A1
· La Rosa et al.
· 2004
[cited by applicant]
US 20130332133A1
· Horn et al.
· 2013
[cited by applicant]
US 20150190506A1
· Cheung et al.
· 2015
[cited by applicant]
US 20170290913A1
· Cheung et al.
· 2017
[cited by applicant]
EP 2844289A1
· 2015
[cited by applicant]
JP 2009504191A
· 2009
[cited by applicant]
JP 2013539364A
· 2013
[cited by applicant]
WO 9222583A2
· 1992
[cited by applicant]
WO 2004041862A2
· 2004
[cited by applicant]
WO 2005003169A2
· 2005
[cited by applicant]
WO 2005003170A2
· 2005
[cited by applicant]
WO 2005003171A2
· 2005
[cited by applicant]
WO 2005113605A1
· 2005
[cited by applicant]
WO 2006121810A2
· 2006
[cited by applicant]
WO 2007024715A2
· 2007
[cited by applicant]
WO 2009040562A1
· 2009
[cited by applicant]
WO 2010077634A1
· 2010
[cited by applicant]
WO 2012027570A2
· 2012
[cited by applicant]
WO 2012023053A3
· 2012
[cited by applicant]
WO 2013165690A1
· 2013
[cited by applicant]
WO 2014028776A1
· 2014
[cited by applicant]
WO 2014100079A1
· 2014
[cited by applicant]
WO 2014121099A1
· 2014
[cited by applicant]
WO 2014144357A1
· 2014
[cited by applicant]
WO 2014148895A1
· 2014
[cited by applicant]
WO 2014209804A1
· 2014
[cited by applicant]
WO 2016118733A1
· 2016
[cited by applicant]
WO 2016149201A2
· 2016
[cited by applicant]
WO 2017123673A2
· 2017
[cited by applicant]
WO 2018115003A2
· 2018
[cited by applicant]
Vinay et al. (BMB Rep. Mar. 2014; 47 (3): 122-9).
[cited by examiner]
Lee et al. (J. Immunother. May-Jun. 2004; 27 (3): 201-10).
[cited by examiner]
Bartkowiak et al. (Front. Oncol. 2015; 5: 117; pp. 1-16).
[cited by examiner]
Fidler, IJ. “Biological heterogeneity of cancer”, Human Vaccines & Immunotherapeutics 8:8, pp. 1141-1142 (2012).
[cited by applicant]
Gale, Robert, “Cellular and Molecular Basis of Cancer”, Merck Manuals Online Medical Library, [online]. Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. [retrieved on Oct. 19, 2020]. < URL: https://www.me…
[cited by applicant]
Li et al. “Antibody-based cancer immunotherapy by targeting regulatory T cells,” Frontiers in Oncology 13:1157345. pp. 1-13, (2023).
[cited by applicant]
Muller et al. “Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy”, BioDrugs 37: pp. 21-33, (2023).
[cited by applicant]
Müller, N., et al., ( “Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization”. The FEBS journal, 275(9), 2296-2304 (2008).
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2019/046156, dated Dec. 2, 2019, 12 pages.
[cited by applicant]
Adair et al., “Therapeutic Antibodies” Drug Design Reviews, vol. 2, No. 3, 2005, pp. 209-217(9).
[cited by applicant]
Verma et al., “Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems” J Immunol Methods Jul. 1, 1998;216(1-2):165-81.
[cited by applicant]
Bonifant et al., “Toxicity and management in CAR T-cell therapy”, Mol Ther Oncolytics, 2016, v.20, n.3, p. 16011.
[cited by applicant]
Delia Nelson et al., “The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment”, J. Immunol. Res., 2014, v.2014, art.789069, p. 1-14.
[cited by applicant]
Gura T., “Systems for identifying new drugs are often faulty”, Science, 1997, v.278, n.5340, p. 1041-1042.
[cited by applicant]
Haigh P.I. et al., “Vaccine therapy for patients with melanoma”, Oncology, 1999, v.13, n.11, abstract, 1 page.
[cited by applicant]
Jain R.K., “Barriers to drug delivery in solid tumors”, Sci. Am., 1994, v.271, n.1, p. 58-65.
[cited by applicant]
Lee K.H. et al., Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, J. Immunol., 1999, v.1…
[cited by applicant]
Li J. et al., Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward, J Hematol Oncol., 2018, Feb. 13, 2018, v.11, n.1, p. 22-40.
[cited by applicant]
Muller S. et al., “Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial, Arthritis & Rheumatism:” Official Journal of the American College of Rheumatol…
[cited by applicant]
Prokofieva L.V. et al., “Course of lectures on general pharmacology” teaching aid, Ulyanovsk: UIGU, 2017, 155 pp., pp. 65-77.
[cited by applicant]
Spitler L.E., “Cancer vaccines: the interferon analogy”, Cancer Biother., 1995, v.10, n.1, p. 1-3.
[cited by applicant]
Weinberg et al., “Science gone translational: the OX40 agonist story” Immunol Rev. 244(1): pp. 218-231 (2011).
[cited by applicant]
Pullen et al., “High-Affinity Interactions of Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) and CD40 Require TRAF Trimerization and CD40 Multimerization”, Biochemistry. Aug. 3, 1999; 38 (31): 10168-77.
[cited by applicant]
Rahbarizadeh et al., Nanobody, New Agent for Combating Against Breast Cancer Cells, Breast Cancer—Current and Alternative Therapeutic Modalities, pp. 347-370 (2011).
[cited by applicant]
Rizo et al. “Constrained Peptides: Models of Bioactive Peptides and Protein Substructures”, Ann. Rev. Biochem., 1992, vol. 61, p. 387-418.
[cited by applicant]
Rossi et al. “Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma”, Blood. Jun. 11, 2009; 113 (24): 6161-6171.
[cited by applicant]
Saerens et al., “Identification of a Universal VHH Framework to Graft Non-canonical Antigen-binding Loops of Camel Single-domain Antibodies”, J. Mol. Biol. Sep. 23, 2005; 352 (3): 597-607.
[cited by applicant]
Safdari et al., “Antibody humanization methods-a review and update”, Biotechnology and Genetic Engineering Reviews, 2013, V. 29, N. 2, p. 175-186.
[cited by applicant]
Sanmamed et al.: “Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rynull Immunodeficient Mice”, Cancer Research, (75)(17), pp. 3466-3478, Sep. 1, 2015.
[cited by applicant]
Search Report issued in corresponding Singaporean application No. 11201805422W, dated Sep. 18, 2019, 4 pages.
[cited by applicant]
Shields et al. “High-Resolution Mapping of the Binding Site on Human IgG 1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG 1 Variants with Improved Binding to the FcyR”, The Journal of Biological Chemistry, 2001,…
[cited by applicant]
Smith et al. “Comparison of Biosequences”, 1981, Advances in Applied Mathematics, vol. 2, p. 482-489.
[cited by applicant]
Stavenhagen et al. “Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization”, Advances in Enzyme Regulations, 2008, vol. 48, p. 152-164.
[cited by applicant]
Stavenhagen et al. “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fey Receptors”, Cancer Research, 2007, v…
[cited by applicant]
Stec et al. “Automated Solid-Phase Synthesis, Separation, and Stereochemistry of Phosphorothioate Analogues of Oligodeoxyribonucleotides”, J. Am. Chem. Soc., 1984, vol. 106, No. 20, p. 6077-6079.
[cited by applicant]
Stein et al. “Physicochemical properties of phosphorothioate oligodeoxynucleotides”, Nucl. Acids Res., 1988, vol. 16, No. 8, p. 3209-3221.
[cited by applicant]
Teplyakov et al., “Antibody modeling assessment II Structures and models”, Proteins: Structure, Function, and Bioinformatics, 2014, V. 82, N. 8, p. 1563-1582.
[cited by applicant]
Thornton et al. “Prediction of progress at last”, Nature, 1991, vol. 354, p. 105-106.
[cited by applicant]
Uhlmann et al. “Antisense Oligonucleotides: A New Therapeutic Principle”, Chemical Reviews, 1990, vol. 90, No. 4, p. 544-584.
[cited by applicant]
Veber et al. “The design of metabolically-stable peptide analogs”, TINS, Sep. 1985, p. 392-396.
[cited by applicant]
Vincke et al. “General Strategy to Humanize a Camelid Single-Domain Antibody and Identification of a Universal Humanzied Nanobody Scaffold”, J. Biol. Chem. Jan. 30, 2009; 284 (5): 3273-84.
[cited by applicant]
Vincke et al. “Generation of Single Domain Antibody Fragments Derived from Carnelids and Generation of Manifold Constructs”, Methods Mol. Biol. 2012; 907: 145-76.
[cited by applicant]
Wesolowski et al. “Single Domain antibodies: promising experimental and therapeutic tools in infection and immunity”, Med. Microbiol. Immunol. Aug. 2009; 198 (3): 157-174).
[cited by applicant]
Yada A. et al. “A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes”, Annals of Oncology, 2008, vol. 19, p. 1060-1067.
[cited by applicant]
Zalevsky et al. “Enhanced antibody half-life improves in vivo activity”, Nature Biotechnology, 2010, vol. 28, No. 2, p. 157-159.
[cited by applicant]
Zhang et al. “Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DRS and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model”, Cancer Letters, 2007, vol. 251, p. 146-157.
[cited by applicant]
Zhang et al., “Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade,” Cell Disco. vol. 3: 1-12, 2017.
[cited by applicant]
Zon et al. “Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions”, Anti Cancer Drug Design, 1991, vol. 6, p. 539-568.
[cited by applicant]
Zon et al., “Phosphorothioate oligonucleotides”, in Oligonucleotides and Analogues: A Practical Approach, 1991, pp. 87-108.
[cited by applicant]
Alegre et al. “Effect of a single amino acid mutation on the activating and immunosuppressive properties of a humanized OKT3 monoclonal antibody”, The Journal of immunology, 1992, vol. 148, p. 3461-3468.
[cited by applicant]
Bannas et al. “Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics,” Front. Immunol., 2017; vol. 8:1603; pp. 1-13.
[cited by applicant]
Barker et al., “Detecting Distant Relationships: Computer Methods and Results”, in Dayhoff, M.O., Atlas of Protein Sequence and Structure, 1972, vol. 5, pp. 101-110.
[cited by applicant]
Blanco-Toribio et al. “Generation and characterization of monospecific and bispecific hexavalent trimerbodies”, MAbs. Jan.-Feb. 2013; 5 ( 1 ): 70-9.
[cited by applicant]
Borisov et al., “Tumor microenvironment as a target of malignant gliomas treatment”, Malignant Tumours 2015; 4:14-23.
[cited by applicant]
Bowie et al. “A Method to Identify Protein Sequences That Fold into a Known Three-Dimensional Structure”, 1991, Science, vol. 253, p. 164-170.
[cited by applicant]
Bulliard et al. “Activating Fc y receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies”, J. Exp. Med., vol. 210, No. 9, p. 1685-1693.
[cited by applicant]
Bulliard et al. “OX40 engagement depletes intratumoral Tregs via activating FcyRs, leading to antitumor efficacy”, Immunology and Cell Biology, 2014, vol. 92, p. 475-480.
[cited by applicant]
Carter, “Bispecific human IgG by design”, Journal of immunological Methods, 2001, vol. 248, p. 7-15.
[cited by applicant]
Chen et al “Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model”, Cancer Immunology research. vol. 3, No. 2; pp. 149-160; Nov. 11, 2014.
[cited by applicant]
Chen et al., “Fusion protein linkers: property, design and functionality”, Advanced drug delivery reviews, 2013, V. 65, N. 10, p. 1357-1365.
[cited by applicant]
Chothia et al. “Canonical Structures for the Hypervariable Regions of immunoglobulins”, J. Mol. Biol., 1987, vol. 196, p. 901-917.
[cited by applicant]
Chothia et al. “Conformations of immunoglobulin hypervariable regions”, Nature, 1989, vol. 342, p. 878-883.
[cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology”, 1994, V. 145, N. 1, p. 33-36.
[cited by applicant]
Cuesta et al., “Improved stability of multivalent antibodies containing the human collagen XV trimerization domain”, MAbs. Mar.-Apr. 2012; 4 (2): 226-32.
[cited by applicant]
Cuesta et al., “Multivalent antibodies: when design surpasses evolution”, Cell Press Trends in Biotechnology (28), pp. 355-362 (2010).
[cited by applicant]
Dall' Acqua et al. “Properties of Human IgG Is Engineered for Enhanced Binding to the Neonatal Fe Receptor (FcRn)”, The Journal of Biological Chemistry, 2006, vol. 281, No. 33, p. 23514-23524.
[cited by applicant]
Davies et al. “Antibody-Antigen Complexes”, Annual Rev Biochem, 1990, vol. 59, p. 439-473.
[cited by applicant]
Dayhoff, M.O., “Survey of New Data and Computer Methods of Analysis”, in Atlas of Protein Sequence and Structure, 1976, vol. 5, Supplement 2, p. 1-8.
[cited by applicant]
European Search Report issued in EP 17738885.7, dated Jul. 8, 2019, 8 pages.
[cited by applicant]
Evans et al. “Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin Antagonists”, J. Med. Chem., 1987, vol. 30, p. 1229-1239.
[cited by applicant]
Fauchere, “Elements for the Rational Design of Peptide Drugs”, Advances in Drug Research, 1986, vol. 15, p. 29-69.
[cited by applicant]
Fisicaro et al., “Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV”, Gastroenterology (143)(6), pp. 1576-1585, Dec. 1, 2012.
[cited by applicant]
Graves et al. “Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity”, Cancer Cell, 2014, vol. 26, p. 177-189.
[cited by applicant]
He et al., “Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies”, Oncotarget, vol. 8: 67129-67139, 2017.
[cited by applicant]
Holliger et al., “Engineered antibody fragments and the rise of single domains”, Nat. Biotechnol. Sep. 2005; 23 (9): 1126-36.
[cited by applicant]
Huet et al., “Mulivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction”, MAbs. 2014; 6 (6): 1560-70.
[cited by applicant]
Ichikawa et al. “Tumoricidal activity of a novel anti-human DRS monoclonal antibody without hepatocyte cytotoxicity”, 2001, Nature Medicine, vol. 7, No. 8, p. 954-960.
[cited by applicant]
Dusogie et al. “Engineered Antibodies with Increased Activity to Recruit Complement”, The Journal of immunology, 2001, vol. 166, p. 2571-2575.
[cited by applicant]
Iezzi et al., “Promise of Modular Targeting in Cancer Imaging and Treatment”, Frontiers in Immunology, vol. 9: 1-11, 11 pages, Feb. 19, 2018.
[cited by applicant]
Inman et al., “Utomilumab/Pembrolizumab Combo Shows responses in Different Solid Tumors”, XP002793239, Retrieved from the Internet: URL:https://www.targetedonc.com/conference/asco-immune-2016/utomiluma/pembrolizumab; 2 …
[cited by applicant]
International Search Report and Written Opinion for PCT/US17/13070 dated Jun. 30, 2017; 26 pages.
[cited by applicant]
Kaneko et al. Optimizing Therapeutic Antibody Function,, Biodrugs, 2011, vol. 25, No. 1, p. 1-11.
[cited by applicant]
Kjaergaard et al. “Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor”, J. Immunol. Dec. 1, 2001; 167 (11): 6669-77.
[cited by applicant]
Kontermann et al., “Bispecific antibodies”, Drug Discovery Today, 2015, V. 7, N. 20, p. 838-847.
[cited by applicant]
LaPlanche et al. “Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscoptc studies of the Rp-Rp, Sp-Sp, and RrSP duplexes, [dCGGsAATTCC]2, derived from diastereomeric 0-ethyl phosphorothioates”…
[cited by applicant]
Lazar et al. “Engineered antibody Fc variants with enhanced effector function”, PNAS, 2006, vol. 103, No. 11, p. 4005-4010.
[cited by applicant]
Li et al. “LBY135, a Novel Anti-DRS Agonistic Antibody Induces Tumor Cell-Specific Cytotoxic Activity in Human Colon Tumor Cell Lines and Xenografts”, Drug Development Research, 2008, vol. 69, p. 69-82.
[cited by applicant]
Linch S. et al., “OX40 agonists and combination immunotherapy: putting the pedal to the metal”, Frontiers in Oncology, Feb. 16, 2015, vol. 5, pp. 34:1-14.
[cited by applicant]
Locksley et al., “The TNF and TNF receptor superfamilies: integrating mammalian biology”, Cell, 2001, V. 104, N. 4, p. 487-501.
[cited by applicant]
Maeda et al., “Engineering of functional chimeric protein G-Vargula Luciferase”, Analytical biochemistry, 1997, V. 249, N. 2, p. 147-152.
[cited by applicant]
Malmqvist, M. “Biospecific interaction analysis using biosensor technology”, Nature, 1993, vol. 361, p. 186-187.
[cited by applicant]
Moore et al., “Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector function”, mAbs, 2010, vol. 2, No. 2, p. 181-189.
[cited by applicant]
Morris et al., “Development and Characterization of Recombinant Human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain”, Mol. Immunol. May 2007; 44 (12): 3112-21.
[cited by applicant]
Muller, Dafne et al., “Recombinant bispecific antibodies for cellular cancer immunotherapy”, Current opinion in Molecular Therapeu, Current Drugs, London GB, (9)(4), Aug. 1, 2007, pp. 319-326.
[cited by applicant]
Natsume et al. “Engineered Antibodies of IgG 1/IgG 3 Mixed Isotype with Enhanced Cytotoxic Activities”, Cancer Research, 2008, vol. 68, No. 10, o. 3863-3872.
[cited by applicant]
Needleman and Wunsch “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, J. Mol. Biol., 1970, vol. 48, p. 443-453.
[cited by applicant]
Nelson et al., “The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment”, J. Immunol. Res., 2014, N.789069, pp. 1-14.
[cited by applicant]
Pearson et al. “Improved tools for biological sequence comparison”, 1988, Proc. Natl. A.cad. Sci. USA, vol. 85, p. 2444-2448.
[cited by applicant]
Pukac et al. “HGS-ETRI, a fully human TRAIL-receptor I monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo”, British Journal of Cancer, 2005, vol. 92, p. 1430-1441.
[cited by applicant]
Hino et al., “G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody” Nature 482, pp. 237-241 (2012).
[cited by applicant]